Amicus Therapeutics, Inc.

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a leading biotechnology company focused on developing innovative therapies for rare and orphan diseases. Established with a mission to transform the lives of patients suffering from these conditions, Amicus is dedicated to advancing the science of protein replacement therapy and gene therapy.

The company’s flagship product, Galafold (migalastat), is a first-in-class oral treatment for Fabry disease, showcasing Amicus’s commitment to addressing unmet medical needs. In addition to Galafold, Amicus is actively engaged in developing a robust pipeline of therapies targeting various lysosomal storage disorders.

Amicus Therapeutics operates with a strong emphasis on patient-centricity, ensuring that the voices of patients and their families are integral to the development process. The company collaborates with healthcare professionals, researchers, and advocacy groups to enhance understanding and treatment options for rare diseases.

With headquarters located in the UK, Amicus Therapeutics is strategically positioned to leverage global partnerships and expand its reach in the biopharmaceutical industry. The company is committed to maintaining high standards of quality and compliance in all its operations.

Amicus Therapeutics is also focused on sustainability and corporate responsibility, striving to make a positive impact on the communities it serves. Through its innovative research and development efforts, Amicus aims to lead the way in transforming the treatment landscape for patients with rare diseases.

• Core Activities: Development of therapies for rare diseases
• Vision: To transform the lives of patients through innovative treatments
• Commitment: Patient-centric approach and collaboration with stakeholders